Uso de la dapagliflozina en el tratamiento de la diabetes mellitus tipo 2
Hernández Rodríguez, José; Licea Puig, Manuel Emiliano.
Rev. cuba. endocrinol
; 27(2): 0-0, mayo.-ago. 2016.
Artículo en Español | LILACS | ID: lil-780735
Documentos relacionados
Should Acupuncture-Related Therapies be Considered in Prediabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.
Effect of glycosylated hemoglobin protein molecule in treating diabetes.
Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus.
Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine.
Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Glycated Haemogloin, Fasting Plasma Glucose, Plasminogen Activator Inhibitor Type-1, and Soluble Thrombomodulin Levels in Patients with Type 2 Diabetes Mellitus.
The use of glycosylated hemoglobin (HbA1c) as a predictor of the severity of acute coronary syndrome among diabetic patients.